Corvus Pharmaceuticals, Inc. (CRVS) · Nov 5, 2026 · Earnings
Miss — diluted EPS $(0.22) vs ~$0.19 loss consensus
Corvus earnings slightly missed the published EPS estimate, while trial enrollment stays on track and cash funds operations into Q2 2028.
Corvus is a clinical-stage biotech using soquelitinib to pursue a two-track story: a registrational Phase 3 PTCL program alongside expanding immunology trials in atopic dermatitis, hidradenitis suppurativa and asthma. Its near-term investment case remains driven by clinical milestones rather than revenue, with the company previously positioning its cash balance to fund operations into the second quarter of 2028.
The quarter was a modest earnings miss, not a pipeline setback. Diluted EPS was $(0.22), versus a published Q3 consensus of roughly $(0.19), while research spending more than doubled year over year as clinical-trial activity expanded. That makes the financial result slightly worse than expected, but the miss reflects higher development spending rather than a disclosed program delay.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Diluted EPS (Income Statement) | $(0.22) | $(0.12) | $(0.19) |
| R&D expense (Income Statement) | $17.8M (+110.3%) | $8.5M | |
| Net loss (Income Statement) | $(20.3)M (+100.2%) | $(10.2)M | |
| Cash and marketable securities (Balance Sheet) | $202.9M | $56.8M |
Execution remains broadly on schedule. Corvus says enrollment in the Phase 3 PTCL and Phase 2 atopic dermatitis studies is on track, while its new hidradenitis suppurativa study is enrolling and the asthma Phase 2 trial remains planned for the first quarter of 2027. 〔0〕 The new information is mainly milestone confirmation and timing, not clinical efficacy data that changes the probability of success.
The China partnership adds a defined 2027 data point, but not yet validation. Angel Pharmaceuticals completed enrollment of the first 24-patient atopic dermatitis cohort, with topline results expected in March 2027. The small cohort can provide an early signal, but it is still a future readout rather than evidence that soquelitinib works in the broader Phase 2 population.
Funding remains a meaningful cushion, though spending is accelerating. Cash and marketable securities were $202.9 million at September 30, down from $215.2 million at June 30 based on the prior quarter's filing, while the company retained its expectation of funding operations into Q2 2028. The runway is therefore unchanged, but the higher R&D burn makes future trial costs the key balance-sheet variable. 〔1〕
Bottom line: This is a small earnings miss against a largely intact development story. The filing keeps Corvus on track for its 2027 clinical catalysts, but adds no efficacy result strong enough to materially rewrite the investment case today.
Angel Pharma atopic dermatitis data, March 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!